Country for PR: United States
Contributor: PR Newswire New York
Thursday, September 03 2020 - 18:49
New investors Thiel and Novogratz introduced to Bionomics by Apeiron Investment Group as part of successful second placement capital raising
SYDNEY, Sept. 3, 2020 /PRNewswire-AsiaNet/ --

Following overwhelming shareholder approval, the scheduled second placement of 
54,333,000 new shares by Bionomics is proceeding and expected to complete 
shortly. In accordance with the Subscription Agreement between Apeiron and 
Bionomics, Apeiron has introduced Michael Novogratz, Peter Thiel, and Jason 
Camm, Managing Director of Lifesciences at Thiel Capital, to Bionomics. Each of 
these investors, along with Aperion, will subscribe for ordinary shares in 
Bionomics as part of the scheduled second placement.  

Apeiron's backing has ensured that the Company has the funds needed to make 
significant progress in its Phase II clinical trials of BNC210 for PTSD. BNC210 
recently received Fast Track Designation from the U.S. Food and Drug 
Administration (FDA) for the treatment of PTSD. 

In addition to BNC210, Bionomics is collaborating with Merck US on several 
compounds for the treatment of cognitive deficits in Alzheimer's and 
Schizophrenia. The Company also has promising oncology assets undergoing Phase 
II clinical trials funded by Bristol Myers-Squibb and other pharma partners.

Apeiron Contact
Aaron Weaver
Head of Capital Markets, Apeiron Investment Group
+44 (0) 7850009833 

About Apeiron Investment Group 
Apeiron Investment Group Ltd, Malta, is the family office and merchant banking 
business of Christian Angermayer. Apeiron focuses on Financial Services 
(especially fintech and crypto assets), Deep-Tech (AI, space-tech, 
cybersecurity etc.), Life Sciences, Media & Entertainment and Real Estate & 

About Bionomics Limited 
Bionomics is a biopharmaceutical company dedicated to making better treatments 
for cancer, central nervous system disorders such as anxiety, depression and 
Alzheimer's Disease. Based in Adelaide, Australia, with operations in San 
Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is 
listed on the Australian Securities Exchange (ASX) under the code BNO, and the 
US OTCQX market under the code BNOE.

Source: Apeiron Investment Group